Study Population
HYPERTENSION
Of the full analysis set from the randomized trial (n=1161), 632 patients (54% in total, 56% treated with sacubitril/valsartan 200 and 400 mg/d and 51% treated with olmesartan) had ambulatory BP data at baseline and follow‐up and were included in this analysis (Patient Demographics and Clinical Characteristics at Baseline, Overall, and by Treatment GroupValues are the number of patients (%) or mean±standard deviation. ACE indicates angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; PP, pulse pressure; and SBP, systolic blood pressure.Data are available from 403 patients.Three patients (1 in each treatment group) had treatment‐naïve hypertension.